製藥 業務的一部分 生命科學.
人們仰賴製藥產業提供改善生活品質的救命藥物和治療方法。即使在研發上投入數十億美元,也只有少許新藥能通過臨床試驗和符合進入市場所需的嚴格監管許可。對於這樣的企業,至關重要的是,公司必須保護奠基新藥和療法的智慧財產。Finnegan飛翰與創新的製藥公司合作已有悠久的歷史,旨於保護和最大化其寶貴的智財權與資產,為智財申請和組合擬訂策略。
我們客戶的業務和智財資產是全球性的,在各轄區保護這些資產變得越來越挑戰。結合我們在全球設立的據點和與跨國公司的合作經驗,Finnegan飛翰擁有的資源和經驗,得以為製藥公司制訂及執行全球戰略。因應新發現及其商業應用的快速進展,需要對智財權的法律議題和產業的理解能夠充分掌握,以洞悉這些進步的科學和戰略意涵。
憑藉為製藥客戶解決幾乎各類型之智財議題的經驗,我們透過以下方式提供協助:
我們與客戶一起在眾多領域中致力科學的創新與推進,包括:
我們的生命科學業務由250多位律師和專業人士組成,致力於滿足客戶對於智財權服務的需求。多數擁有與生物學,化學,生物化學,醫學,藥理學,或生醫工程等相關學科的高階學位。大多具有紮實的研究和/或產業經驗,許多人在產業或大學任職,或在美國專利商標局擔任審查委員後加入Finnegan飛翰。
In a rare rehearing proceeding, successfully represented petitioner Incyte in an inter partes review (IPR) challenging the validity of Concert’s patent before the Patent Trial and Appeal Board (PTAB). Continued representation of appellee Incyte before the Federal Circuit and secured a unanimous affirmance of the PTAB’s obviousness determination.
IPR2017-01256, PTAB, Judges Fitzpatrick, Hulse, Yang, Smith, Franklin
19-2011, Fed. Cir., Judges Hughs, Linn, Stark
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
IPR2022-01200, PGR2022-00051, PTAB, Judges Newman, Snedden, Wisz
22-2232, Fed. Cir.
PGR2022-00037, PTAB, Judges Newman, Obermann, Worth
IPR2022-00738, -00739, -00796, PTAB, Judges Cotta, Wisz, Worth
1:21-cv-10954, D. Mass., Judge Burroughs
1:21-cv-02258, 1:21-cv-02899, N.D. Ill., Judge Lee
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Award/Ranking
Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon
October 30, 2023
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Award/Ranking
Finnegan Shortlisted in 10 Categories in the LMG Life Sciences Awards 2023
July 25, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.